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Introduction: So far, no study has summarized the findings on the effects of berberine intake on
anthropometric parameters, C-reactive protein (CRP) and liver enzymes. This systematic review and
meta-analysis were done based upon randomized controlled trials (RCTs) to analyze the effects of
berberine on anthropometric parameters, CRP and liver enzymes.
Method: Following databases were searched for eligible studies published from inception to 30 July
2019: MEDLINE, EMBASE, Web of Science, Cochrane Library, PubMed and Google scholar. Necessary data
were extracted. Data were pooled by the inverse variance method and expressed as mean difference with
95% Confidence Intervals (95% CI).
Result: 12 studies were included. Berberine treatment moderately but significantly decreased body
weight (WMD ¼ 2.07 kg, 95% CI -3.09, 1.05, P < 0.001), body mass index (BMI) (WMD ¼ 0.47 kg/m2,
95% CI -0.70, 0.23, P < 0.001), waist circumference (WC) (WMD ¼ 1.08 cm, 95% CI -1.97, 0.19,
P ¼ 0.018) and C-reactive protein (CRP) concentrations (WMD ¼ 0.42 mg/L, 95% CI -0.82, 0.03,
P ¼ 0.034). However, berberine intake did not affect liver enzymes, including alanine aminotransferase
(ALT) (WMD ¼ 1.66 I/U, 95% CI -3.98, 0.65, P ¼ 0.160) and aspartate aminotransferase (AST)
(WMD ¼ 0.87 I/U, 95% CI -2.56, 0.82, P ¼ 0.311).
Conclusion: This meta-analysis found a significant reduction of body weight, BMI, WC and CRP levels
associated with berberine intake which may have played an indirect role in improved clinical symptoms
in diseases with metabolic disorders. Berberine administration had no significant effect on ALT and AST
levels.
© 2020 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights
reserved.ence-Based Health Manage-
gheh, Iran.
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ition and Metabolism. Published b
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-analysis of randomized c1. Introduction
Increased body weight is associated with different diseases,
particularly cardiovascular diseases (CVD), type 2 diabetes mellitus
(T2DM), obstructive sleep apnea, some types of cancer, osteoar-
thritis and depression [1]. In addition, nonalcoholic fatty liver dis-
ease (NAFLD) and elevated liver enzymes are closely linked to
several metabolic syndrome features [2,3]. Recent research proved
that populations with elevated basal concentrations of C-reactivey Elsevier Ltd. All rights reserved.
ementation on obesity parameters, inflammation and liver function
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Fig. 1. Flowchart of the study selection for inclusion in the systematic reviews and meta-analyses.
O. Asbaghi et al. / Clinical Nutrition ESPEN xxx (xxxx) xxx2protein (CRP) are at an increased risk of CVD, diabetes and hyper-
tension [4,5]. There is a rising trend to use traditional medicinal
plants, particularly in some parts of the world, because they are
often cheaper and more available or because patients are reluctant
to take drugs and they believe that plants are “more natural” [6,7].
There are some phytochemicals (or nutraceuticals), including
capsaicin, resveratrol, curcumin, green tea epigallocatechin gallate
(EGCG) and berberine, that have effects on thermogenic activation
based upon different modes of action [8]. Berberis vulgaris
(B. vulgaris) is used as pharmaceutical more than 2500 years [9].
Different parts of this plant have specific therapeutic effects.
Berberine, an isoquinoline alkaloid, is the major active part ofPlease cite this article as: Asbaghi O et al., The effect of berberine suppl
enzymes: A systematic review and meta-analysis of randomized c
j.clnesp.2020.04.010B. vulgaris [10]. A meta-analysis by Wei et al. [11] indicated that in
patients with NAFLD, berberine intake was associated with an
improvement in glycemic control, serum lipoproteins and liver
function. Several randomized clinical trials (RCTs) have indicated a
beneficial effect of berberine on anthropometric parameters and
biomarkers of inflammation as well as on liver function in different
conditions [12,13]. However, some other studies could not confirm
such effects [14,15].
There is evidence suggesting that the activation of AMP-
activated protein kinase (AMPK) signaling pathway, which is a
key regulator of energy metabolism and controls inflammatory
processes, can be affected by berberine [16,17]. Berberine can alsoementation on obesity parameters, inflammation and liver function
ontrolled trials, Clinical Nutrition ESPEN, https://doi.org/10.1016/
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O. Asbaghi et al. / Clinical Nutrition ESPEN xxx (xxxx) xxx 3downregulate the expression of pro-inflammatory genes and
those involved in adipocyte differentiation like PPAR-g [18].
Despite these studies, no earlier meta-analysis has summarized
findings on the effects of berberine on anthropometric parame-
ters, CRP and liver enzymes. Therefore, this meta-analysis was
performed to summarize all the existing RCTs evidence and to
evaluate the effects of berberine on anthropometric parameters,
CRP and liver enzymes.
2. Methods
2.1. Search and studies selection strategies
Eligible RCTs were identified using Cochrane Library, Embase,
Medline, Web of Science, PubMed and Google scholar databases
for relevant articles published from inception until 30 July 2019,
and by manually searching the reference list of the located arti-
cles. Studies that evaluated the of berberine intake on anthropo-
metric parameters, CRP and liver enzymes were found by using
the following MeSH and text words: intervention ["berberine” OR
“huangliansu” OR “berberinum” OR “Xiaopojian"], and outcomes
“body weight” OR “body mass index (BMI)" OR “waist circum-
ference (WC)" OR “inflammation” OR “C-reactive protein (CRP)"
OR “alanine aminotransferase (ALT)" OR “aspartate aminotrans-
ferase (AST)". Additional manual searches including reference lists
of related and studies previously published reviews were
reviewed to increase sensitivity of search strategy. Studies
included in this meta-analysis had to fulfill the following criteria:
1) original trials, 2) human trials, 3) written in English and 4) the
trials which reported mean changes or mean difference of
anthropometric parameters, CRP and liver enzymes with standard
deviation (SD) for the intervention and control groups. Other
studies such as in vitro studies, animal experiments, case reports,
trials without a control group, observational studies and studies
that did not achieve the least quality score were excluded from
this meta-analysis.
2.2. Data extraction and quality assessment
Two authors (OA and EA) independently extracted the data
and assessed its quality using standard forms and the Cochrane
Collaboration risk of bias tool [19,20], respectively. This tool is
based on information on the following domains: randomization
generation, allocation concealment, blinding of subjects and
outcome assessment, incomplete outcome data, and selective
outcome reporting, and other sources of bias. When there was
disagreement among them, it was resolved by third author (ZA).
From eligible studies the following data were taken: 1) first au-
thors’ name 2) publication year 3) age, sex, and body composi-
tion and/or metabolic parameters of study participants 4) study
location 5) number of subjects in intervention and control
groups 6) study design 7) duration of the intervention in each
intervention group.
2.3. Data analysis
The effects of berberine intake on the changes of the following
parameters were calculated: 1) anthropometric parameters, 2)
CRP and 3) liver enzymes. Weightedmean difference (WMD) with
95% CI was used for pooling data to determine the effect sizes. The
change score approach was used to calculate the effect size of
berberine consumption on the analyzed parameters. The random-
effect model was used to report the pooled effect sizes using 95%
CI. To calculate the SD changes, the following formula was used:
SD ¼ square root [(SD pre-treatment)2 (SD posttreatment)2 -Please cite this article as: Asbaghi O et al., The effect of berberine supplementation on obesity parameters, inflammation and liver function
enzymes: A systematic review and meta-analysis of randomized controlled trials, Clinical Nutrition ESPEN, https://doi.org/10.1016/
j.clnesp.2020.04.010
O. Asbaghi et al. / Clinical Nutrition ESPEN xxx (xxxx) xxx4(2R  SD pre-treatment  SD post-treatment)], correlation coeffi-
cient (R-value) was considered 0.8 [21]. When an SEM or SE was
reported instead of SD, the SD was calculated based on the
following formula: SD¼ SEM√n (n¼ sample size in each group).
Heterogeneity of included studies was assessed using Cochrane's Q
test (with significant P-value <0.1) and I-square test (I2 greater than
50 percent showing significant heterogeneity). The funnel plot was
used to determine the publication bias. STATA 11.0 (Stata Corp.,
College Station, TX) was applied for data analysis.
3. Results
3.1. Study selection
After initial search in databases, 2315 articles were found. 1025
articles were duplicates and removed. 1290 articles were screened
based on their title and abstract. 1270 publications were excluded
because they were animal studies, reviews or were unrelated with
the topic which was analyzed. 20 articles were eligible to be
analyzed based on the full-text. 8 studies were omitted because the
desired data were lacking. Finally, 12 studies were included in this
systematic review and meta-analysis. The summary of selected
studies is shown in Fig. 1.
3.2. Characteristics of included studies
The main characteristics of the eligible studies are presented in
Table 1. Our analysis included data from 1040 volunteers, 518 in the
berberine arm and 522 in the control arm. Eligible studies were
published between 2005 and 2018. The studies were performed in
China, Italy, Mexico and Iran. All studies were designed as parallel
studies. The trials used different doses of berberine (ranging from
300 mg/day to 1500 mg/day) and trials duration was between 1
month and 24 months. Subjects enrolled in the eligible trials had
allograft renal transplant surgery, T2DM, polycystic ovary syn-
drome (PCOS), acute coronary syndrome, low cardiovascular risk,
metabolic syndrome, NAFLD and acute ischemic stroke. Subjects
enrolled in 4 studies had normal body weight and others were
overweight or obese. The quality assessment of studies is shown in
Table 2.
3.3. Effect of berberine treatment on anthropometric parameters,
CRP and liver enzymes
The effect of berberine intake on bodyweight, BMI,WC, CRP, ALT
and AST was assessed in 5, 8, 5, 4, 4, and 3 studies, respectively.
Berberine treatment significantly decreased anthropometricTable 2
Quality assessment of included studies.
Study (year)
Random Sequence
Generation
Allocation
concealment
Selective outcome
reporting
Wu et al. [53] U H H
Zhang et al. [25] L U L
Gu et al. [14] U H H
Wei et al. [26] L U L
Meng et al. [30] U U L
Derosa et al. [54] L U L
Perez-Rubio et al. [55] L U H
An et al. [56] L U L
Yan et al. [12] L L L
Dai et al. [13] U U L
Zhu et al. [57] U U L
Rashidi et al. [15] L U L
L is low risk of bias; H is high risk of bias; U is unclear risk of bias.
Please cite this article as: Asbaghi O et al., The effect of berberine suppl
enzymes: A systematic review and meta-analysis of randomized c
j.clnesp.2020.04.010including body weight (WMD ¼ 2.07 kg, 95% CI -3.09, 1.05,
P < 0.001; Fig. 2A), BMI (WMD ¼ 0.47 kg/m2, 95% CI -0.70, 0.23,
P < 0.001; Fig. 2B) and WC (WMD ¼ 1.08 cm, 95% CI -1.97, 0.19,
P ¼ 0.018; Fig. 2C) as well as CRP concentrations
(WMD ¼ 0.42 mg/L, 95% CI -0.82, 0.03, P ¼ 0.034; Fig. 2D).
However, berberine intake did not affect liver enzymes, including
ALT (WMD ¼ 1.66 I/U, 95% CI -3.98, 0.65, P ¼ 0.160; Fig. 2E) and
AST (WMD ¼ 0.87 I/U, 95% CI -2.56, 0.82, P ¼ 0.311; Fig. 2F). It has
to be stressed that there was significant heterogeneity for CRP
(I2 ¼ 76.4 and P ¼ 0.005); so we used random-model for pooling
effect sizes. On the other hand, we used the fixed-model for all the
other factors (Fig. 2 A-F).4. Discussion
In this meta-analysis of RCTs, we evaluated the effects of
berberine on anthropometric parameters, CRP and liver enzymes.
This meta-analysis demonstrated that berberine intake was asso-
ciated with improved anthropometric parameters such as body
weight, BMI and WC as well as CRP values, but did not change the
plasma levels of liver enzymes.4.1. Effects on obesity
Obesity is an important component of metabolic syndrome
(MetS) and considered as an important risk factor for different
diseases [22]. Increased inflammatory markers and metabolic
profiles increase the risk of CVD and diabetes [4,5,23,24]. This
meta-analysis demonstrated that berberine reduced body weight,
BMI and WC. Some trials have reported that berberine consump-
tion had beneficial effects on anthropometric mesurments. For
example, Yan et al. [12] reported that 1500 mg of berberine con-
sumption during four months decreased body weight, BMI and WC
in NAFLD patients. Zhang et al. [25] also showed that three months
of berberine consumption at a dosage of 500 mg twice per day
decreased body weight and BMI in T2DM patients with dyslipide-
mia. Another study proved that in women with PCOS berberine
intake during 3 months decreased WC and WHR but without
weight and BMI changes [26]. However, a meta-analysis of animal
models of cancer indicated that berberine intake did not affect body
weight [27]. Obesity can cause insulin resistance and impaired
glucose metabolism which are all components of MetS [28].
Obesity-induced inflammation can exacerbate insulin resistance
[29] and it has been shown that berberine has anti-inflammatory
effects [30]. Most recently it has been shown that berberine can
promote the recruitment and activation of brown adipocyte dif-
ferentiation and thermogenesis epigenetically throughOther sources
of bias
Blinding of participants
personnel
Blinding of
outcome assessors
Incomplete
outcome data
H H H H
U L U L
H L U L
U H L L
H L L L
L L U L
H L U L
H L U L
L H H L
H H H H
H H H L
U L U L
ementation on obesity parameters, inflammation and liver function
ontrolled trials, Clinical Nutrition ESPEN, https://doi.org/10.1016/
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Fig. 2. A-F. Meta-analysis metabolic profiles and anthropometric measurements weighted mean difference estimates for A) Body weight, B) BMI, C) Waist circumference, D) C-
reactive proteine, E) ALT, F) AST in the berberine and placebo groups (CI ¼ 95%).
O. Asbaghi et al. / Clinical Nutrition ESPEN xxx (xxxx) xxx 5AMPKePRDM16 axis, contributing to elevated systemic energy
expenditure and therefore it might have antiadipose effects [31].
It has been shown without any doubt that overweight, obesity
and higher WC are associated with increased mortality [32,33].
Obesity is not only an important risk factor for cardiovascular
diseases and T2DM but also risk factor for different types of cancer
[34]. Therefore, weight management has many favorable effects.
Weight reduction decreases the risk of developing diabetes
[35,36]. In obese subject and patients with essential hypertension,
weight reduction is associated with a decrease in blood pressure
[37,38]. It has been demonstrated that modest weight lossPlease cite this article as: Asbaghi O et al., The effect of berberine suppl
enzymes: A systematic review and meta-analysis of randomized c
j.clnesp.2020.04.010improves pulse wave velocity which is a marker of arterial stiff-
ness [39]. Berberine most probably achieves anti-obesity effects
by modulating the expression of transcription factors and genes
involved in the adipogenesis such as cAMP-response element-
binding (CREB) protein [40], GATA-2 and GATA-3 [41], and PPAR-g
[42] which are associated with the inhibition of adipocyte differ-
entiation. Berberine also enhances the expression of uncoupling
protein 1 (UCP1) and other thermogenic genes in white and
brown adipose tissue and primary adipocytes by a pathway
involving AMPK and PPAR-g coactivator-1 alpha [43]. Moreover,
evidence from animal studies indicated that berberine modifiesementation on obesity parameters, inflammation and liver function
ontrolled trials, Clinical Nutrition ESPEN, https://doi.org/10.1016/
O. Asbaghi et al. / Clinical Nutrition ESPEN xxx (xxxx) xxx6gut microbiota, which decrease insulin resistance, and inflam-
mation and finally improve body weight [44].
4.2. Effects on liver function and CRP
In this meta-analysis, we found that berberine intake decreased
CRP, while ALT and AST levels remained unchanged. Overall, pool-
ing information from all qualified RCTs, provides more precise and
powerful evidence than those from the individual studies. How-
ever, these studies are heterogeneous with respect to study dura-
tion, sampling method, age ranges, dosage of berberine used, the
characteristics of participants, differences between intervention
and control groups, cross-over design or parallel design, allocation
concealment, and dietary intake of participants. In particular, the
wide variation in the amount and formulation of berberine may be
the most important contributor to the heterogeneity seen in our
results. In a study by Meng et al. [30], 600 mg/day of berberine did
not have any effect on AST or ALT. Although our meta-analysis
indicated that berberine had no significant effect on liver en-
zymes, some animal studies suggested that berberine treatment
might have some hepatoprotective effects by suppression of
oxidative stress, inflammatory responses and hepatocyte necrosis
[45,46]. A study by Dai et al. [13] indicated that the consumption of
300 mg/day of berberine with a two-week no-treatment interval
every five months decreased CRP levels in patients with T2DM
during 24 months. A previous meta-analysis by Wei et al. [11]
suggested that berberine can improve liver function in NAFLD pa-
tients. Nevertheless, in two studies on T2DM patients with dysli-
pidemia [25] and patients with ACS [30], berberine did not improve
CRP levels. Inflammation is associated with the pathogenesis of
atherosclerosis [47]. There is evidence that elevated CRP is associ-
ated with a number of diseases including hypertension, CVD, T2DM
and its complications, as well as some other diseases such as Alz-
heimer and Parkinson disease [48]. In general population, increased
CRP levels can independently predict the risk of all-cause and
cardiovascular mortality [49]. Several mechanisms have been pro-
posed for the anti-inflammatory effects of berberine, including
modulation of gut microbiota and intestinal permeability [50],
decreased expression of nuclear factor-kappa B (NF-kB) [51], and
activation of AMPK/mTOR signaling pathway [16] as well as some
other possible mechanisms [52].
The present meta-analysis is among rare studies that summa-
rize findings from earlier studies on anthropometric parameters,
CRP and liver enzymes. Therefore it is important to consider some
limitations of this meta-analysis when interpreting the results and
producing conclusions. This meta-analysis had few limitations. One
of the most important was that subjects in the included studies had
different diseases, including diabetes, non-alcoholic fatty liver
disease, PCOS and CVD which might have an influence on the re-
sults. Moreover, due to the heterogeneity between studies, evident
from the variations in duration of berberine intake, the dosage and
frequency of berberine used, results should be interpreted with
caution. The number of studies and sample size of participant's
study that finally entered to the current meta-analysis was low.
This meta-analysis cannot support the beneficial effects of
berberine supplementation on body weight, BMI, WC and CRP
levels due to low number of studies and high heterogeneity in the
included studies.
5. Conclusions
This meta-analysis found a significant reduction of body weight,
BMI,WC and CRP levels associatedwith berberine intake. Berberine
administration had no significant effect on ALT and AST levels.
Therefore, berberine intake may have played an indirect role inPlease cite this article as: Asbaghi O et al., The effect of berberine suppl
enzymes: A systematic review and meta-analysis of randomized c
j.clnesp.2020.04.010improved clinical symptoms in diseases with metabolic disorders
due to its effect on body weight, BMI, WC and CRP levels.Practical applications
This meta-analysis demonstrated that berberine supplementa-
tion significantly reduced decrease body weight, BMI, waist
circumference and C-reactive protein plasma levels, but did not
affect ALT and AST levels. Therefore, berberine supplementation
may have played an indirect role in improved clinical symptoms in
diseases with metabolic disorders due to its effect on anthropo-
metric indices and C-reactive protein plasma levels.Funding
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